Dag Nesse appointed as Director of Clinical Operations
REYKJAVIK, ICELAND – 15 June 2022 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has appointed Dag Nesse as Director of Clinical Operations with immediate effect.
Dag brings 24 years of experience within the pharmaceutical industry, having also attended the Norwegian Business School, as well as previously being a registered nurse. He has worked across all phases of clinical development has a strong understanding of clinical research. His experience ranges from big pharma to CROs and smaller biotech companies. He has been involved in clinical operations across strategic, tactical, and operational roles and has worked across the Middle East, Asia Pacific, North America and Europe.
Dag joins EpiEndo from Calliditas Therapeutics, where he was Senior Director, Head of Clinical Operations and grew a successful clinical operations team. Prior to that he was Head of Operations at Modus Therapeutics, having held clinical management roles at several CROs. His pharma experience also includes Boston Scientific and MSD Norway.
Maria Bech, CEO of EpiEndo commented:
“Dag brings a wealth of experience in developing and growing clinical operations across all sizes of pharma and biotech businesses. His expertise in planning, executing and managing clinical studies and the associated regulatory environment will be key as we drive our lead asset further through clinical development.”